Trautmann, M.E.; Choi, I.Y.; Kim, J.K.; Sorli, C.H.
Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany, October, 2018.
About this Poster:
Efpeglenatide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) in development for the treatment of type 2 diabetes. The effects of efpeglenatide vs those of liraglutide and dulaglutide on glucodynamics and weight/lipid profiles were studied over 4 weeks in mouse models of diabetes (db/db) and obesity (diet-induced obesity [DIO]), respectively; doses tested were efpeglenatide 1.45, 2.89, or 4.35 nmol/kg once every 2 days (Q2D); twice-daily liraglutide 30 nmol/kg (db/db study) or 50 nmol/kg (DIO study); and dulaglutide 0.98 or 1.96 nmol/kg Q2D (human equivalent doses/key results in Table).